These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8061423)

  • 21. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
    Petersein J; Saini S; Weissleder R
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic resonance imaging of liver metastases: experimental comparison of anionic and conventional superparamagnetic iron oxide particles with a hepatobiliary contrast medium during dynamic and uptake phases.
    Kaufels N; Korn R; Wagner S; Schink T; Hamm B; Taupitz M; Schnorr J
    Invest Radiol; 2008 Jul; 43(7):496-503. PubMed ID: 18580332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble-type hepatobiliary contrast agents for MR imaging.
    de Haën C; Gozzini L
    J Magn Reson Imaging; 1993; 3(1):179-86. PubMed ID: 8428085
    [No Abstract]   [Full Text] [Related]  

  • 24. Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging.
    Choi JY; Kim MJ; Kim JH; Kim SH; Ko HK; Lim JS; Oh YT; Chung JJ; Yoo HS; Lee JT; Kim KW
    Eur J Radiol; 2006 Oct; 60(1):84-90. PubMed ID: 16920315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eovist Injection and Resovist Injection: two new liver-specific contrast agents for MRI.
    Mintorovitch J; Shamsi K
    Oncology (Williston Park); 2000 Jun; 14(6 Suppl 3):37-40. PubMed ID: 10887650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media].
    Di Cesare E; Cariello G; Barile A; Sabatini M; Michelini O; Erriquez D; Masciocchi C
    Radiol Med; 2000 Oct; 100(4):245-50. PubMed ID: 11155451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents].
    Ba-Ssalamah A; Happel B; Kettenbach J; Dirisamer A; Wrba F; Längle F; Schima W
    Radiologe; 2004 Dec; 44(12):1170-84. PubMed ID: 15551031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis of fatty liver with MR imaging.
    Kreft BP; Tanimoto A; Baba Y; Zhao L; Chen J; Middleton MS; Compton CC; Finn JP; Stark DD
    J Magn Reson Imaging; 1992; 2(4):463-71. PubMed ID: 1633400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Detection of liver lesions with gadolinium-enhanced VIBE sequence in comparison with SPIO-enhanced MRI].
    Heim P; Steiner P; Schoder V; Dieckmann C; Kuhlencordt R; Adam G
    Rofo; 2003 Oct; 175(10):1376-83. PubMed ID: 14556107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects.
    Clément O; Siauve N; Cuénod CA; Frija G
    Top Magn Reson Imaging; 1998 Jun; 9(3):167-82. PubMed ID: 9621405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
    J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
    Rofsky NM; Earls JP
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New contrast agents for imaging the liver.
    Helmberger T; Semelka RC
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.
    Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D
    Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Organ specific MRI contrast media in general practice].
    Schima W
    Wien Med Wochenschr Suppl; 2002; (113):8-11. PubMed ID: 12621828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
    Rummeny EJ; Peters PE
    Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real enhancement or merely increased contrast?
    Chen JH
    AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative assessment of gadoxetate disodium, manganese dipyridoxal diphosphate, and superparamagnetic iron oxide for enhancement of the liver in dogs.
    Khangure MS; Hua J
    Acad Radiol; 1996 Aug; 3 Suppl 2():S458-60. PubMed ID: 8796629
    [No Abstract]   [Full Text] [Related]  

  • 40. Contrast agents for MR imaging of the liver.
    Low RN
    J Magn Reson Imaging; 1997; 7(1):56-67. PubMed ID: 9039594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.